demand / volume affecting revenue
“Increases in demand on any of AbbVie's suppliers could result in delays and disruptions in the manufacturing, distribution and sale of its products and/or product shortages, leading to lost revenue.”
ABBV 10-K
Confirmed
Biopharmaceuticals and Care
17 names are moving together; 82% are participating in the current session.
5 observed Confirmed episodes
Co-movement
Observed member paths adjusted against SPY. Shading marks the latest observation window.
Members
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | Healthcare | +0.2% | 1/17 observed active sessions |
| GSK | GSK plc | Healthcare | -0.7% | 2/17 observed active sessions |
| AMGN | Amgen Inc. | Healthcare | -0.7% | 6/17 observed active sessions |
| VRTX | Vertex Pharmaceuticals Incorpor | Healthcare | -1.0% | 3/17 observed active sessions |
| MRK | Merck & Company, Inc. | Healthcare | +0.3% | 2/17 observed active sessions |
| ABBV | AbbVie Inc. | Healthcare | -2.6% | 2/17 observed active sessions |
| INCY | Incyte Corporation | Healthcare | -2.9% | 1/17 observed active sessions |
| RPRX | Royalty Pharma plc | Healthcare | -1.0% | 2/17 observed active sessions |
| BMY | Bristol-Myers Squibb Company | Healthcare | +0.7% | 3/17 observed active sessions |
| ACAD | ACADIA Pharmaceuticals Inc. | Healthcare | -2.5% | Group member |
| HALO | Halozyme Therapeutics, Inc. | Healthcare | -0.9% | 2/17 observed active sessions |
| NBIX | Neurocrine Biosciences, Inc. | Healthcare | -10.3% | 2/17 observed active sessions |
| REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | +3.3% | 5/17 observed active sessions |
| GILD | Gilead Sciences, Inc. | Healthcare | -0.8% | Group member |
| TAK | Takeda Pharmaceutical Company L | Healthcare | -1.0% | 4/17 observed active sessions |
| RDY | Dr. Reddy's Laboratories Ltd | Healthcare | +0.1% | Group member |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | -0.9% | 2/17 observed active sessions |
Why we believe this
Cohort
17 namesParticipation
82% this sessionObserved history
24 daily buildsFiling coverage
14/17 membersdemand / volume
“1,211.0 1,106.7 9% Total revenues $ 2,986.9 $ 2,770.2 8% In the first quarter of 2026 , our U.S. total revenues increased 7% , as compared to the first quarter of 2025 , due to continued strong patient demand, including from new initiations of ALYFTREK, and higher realized net prices in CF, and contributions from CASGEVY and JOURNAVX.”
VRTX 10-Q
product pipeline / R&D affecting expense
“Total R&D, AIPR&D and SG&A Expenses Our total research and development (“R&D”), acquired in-process research and development expenses (“AIPR&D”) and selling, general and administrative (“SG&A”) expenses increased to $1.5 billion in the first quarter of 2026 as compared to $1.4 billion in the first quarter of 2025 , primarily due to increased investment to commercialize our new products .”
VRTX 10-Q
This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
Connected, outside the group
TEVA
HALOsupplier · Not moving with the group now
Filing receipt · TEVA / HALO
“We have commercialized auto-injector products with Teva Pharmaceutical Industries, Ltd.”
HALO · supplier
SNY
BMRNcustomer · Moving with the group now · 115 min observed
Filing receipt · SNY / BMRN
“Sanofi is our sole customer for ALDURAZYME and is responsible for distributing, marketing, and selling ALDURAZYME to third parties.”
BMRN · customer
EXEL
TAKcustomer · Not moving with the group now
Filing receipt · EXEL / TAK
“During the three months ended March 31, 2026, we recognized $7.7 million in revenues in connection with an $8.0 million commercial milestone payment from Takeda, which w…”
TAK · customer
PFE
HALOpartner · Moving with the group now · 115 min observed
Filing receipt · PFE / HALO
“13 Table of Contents Pfizer Collaboration In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide licens…”
HALO · partner
RGNX
ABBVcustomer · Current intraday read unavailable
Filing receipt · RGNX / ABBV
“As of December 31, 2025 and 2024, the Company had recorded $ 10.9 million and $ 11.3 million, respectively, due from AbbVie for net reimbursement of costs incurred for a…”
ABBV · customer
History
2026-07-28 → 2026-08-034 observed active sessions · 0% of active names held across the episode
2026-07-21 → 2026-07-233 observed active sessions · 0% of active names held across the episode
2026-07-15 → 2026-07-162 observed active sessions · 25% of active names held across the episode
2026-07-07 → 2026-07-104 observed active sessions · 0% of active names held across the episode
2026-06-29 → 2026-07-024 observed active sessions · 8.3% of active names held across the episode